VYNE THERAPEUTICS

vyne-therapeutics-logo

VYNE Therapeutics is a clinical late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. We are concurrently evaluating the use of serlopitant for refractory chronic cough, a cough that persists for greater than eight weeks despite treatment of any identified underlying cause. We believe that serlopitant, a highly sel... ective small molecule inhibitor of the neurokinin 1 receptor (NK1-R) given as a once-daily, oral tablet, has the potential to significantly alleviate pruritus and refractory chronic cough symptoms. Pruritus is the primary patient complaint among atopic dermatitis, psoriasis and prurigo nodularis patients and represents a significant patient need. There are currently no therapies approved in the US that are primarily intended to reduce the pruritus associated with these conditions. We expect data from our ongoing Phase 2 clinical trial in pruritus associated with atopic dermatitis in the 2Q18 and from our ongoing Phase 2 clinical trials in pruritus associated with psoriasis and refractory chronic cough by late 2018 or early 2019. We plan to initiate two Phase 3 clinical trials in pruritus associated with prurigo nodularis in the 1H18, with results expected in the 1H20.

#People #Financial #Website #More

VYNE THERAPEUTICS

Social Links:

Industry:
Health Care Pharmaceutical Therapeutics

Founded:
2003-01-01

Address:
Menlo Park, California, United States

Country:
United States

Website Url:
http://www.vynetherapeutics.com

Total Employee:
11+

Status:
Active

Contact:
(650)486-1416

Email Addresses:
[email protected]

Total Funding:
159.8 M USD

Technology used in webpage:
SPF Amazon IPv6 Google Maps Google Maps API Amazon Virginia Region CPanel SSL OpenSSL Akamai Hosted NameBright



Current Advisors List

ted-ebel_image

Ted Ebel Board Member @ VYNE Therapeutics
Board_member
2014-01-01

aaron-royston_image

Aaron Royston Board Member @ VYNE Therapeutics
Board_member
2017-07-01

steve-basta_image

Steve Basta Board Member @ VYNE Therapeutics
Board_member
2016-09-01

elisabeth-sandoval_image

Elisabeth Sandoval Board Member @ VYNE Therapeutics
Board_member
2019-03-01

paul-l-berns_image

Paul L Berns Board Member @ VYNE Therapeutics
Board_member
2017-11-01

scott-whitcup_image

Scott Whitcup Board Member @ VYNE Therapeutics
Board_member
2016-02-01

david-mcgirr_image

David McGirr Board Member @ VYNE Therapeutics
Board_member
2017-11-01

david-domzalski_image

David Domzalski Board Member @ VYNE Therapeutics
Board_member

Current Employees Featured

iain-stuart_image

Iain Stuart
Iain Stuart Chief Scientific Officer @ VYNE Therapeutics
Chief Scientific Officer
2020-03-01

ray-steitz_image

Ray Steitz
Ray Steitz SVP, Human Resources @ VYNE Therapeutics
SVP, Human Resources
2018-11-01

deepa-desai_image

Deepa Desai
Deepa Desai VP, Regulatory Affairs @ VYNE Therapeutics
VP, Regulatory Affairs
2019-03-01

emmanuelle-bellemin_image

Emmanuelle Bellemin
Emmanuelle Bellemin Vice President of Regulatory Affairs and Quality Assurance @ VYNE Therapeutics
Vice President of Regulatory Affairs and Quality Assurance

mutya-harsch_image

Mutya Harsch
Mutya Harsch Chief Legal Officer, General Counsel, & Corporate Secretary @ VYNE Therapeutics
Chief Legal Officer, General Counsel, & Corporate Secretary
2020-03-01

russell-elliott_image

Russell Elliott
Russell Elliott SVP, Pharmaceutical Development @ VYNE Therapeutics
SVP, Pharmaceutical Development
2020-09-01

andrew-saik_image

Andrew Saik
Andrew Saik Chief Financial Officer @ VYNE Therapeutics
Chief Financial Officer
2020-03-01

david-domzalski_image

David Domzalski
David Domzalski Founder & CEO @ VYNE Therapeutics
Founder & CEO
2020-03-01

mark-p-joing_image

Mark P. Joing
Mark P. Joing Vice President of Clinical Operations @ VYNE Therapeutics
Vice President of Clinical Operations

paul-s-kwon_image

Paul S. Kwon
Paul S. Kwon Chief Medical Officer @ VYNE Therapeutics
Chief Medical Officer

Founder


david-domzalski_image

David Domzalski

Stock Details


Company's stock symbol is NASDAQ:VYNE

Acquisitions List

Date Company Article Price
2020-03-09 Foamix Foamix acquired by VYNE Therapeutics N/A

Investors List

remeditex-ventures_image

Remeditex Ventures

Remeditex Ventures investment in Series C - VYNE Therapeutics

presidio-partners_image

Presidio Partners

Presidio Partners investment in Series C - VYNE Therapeutics

rock-springs-capital_image

Rock Springs Capital

Rock Springs Capital investment in Series C - VYNE Therapeutics

f-prime-capital-partners_image

F-Prime Capital

F-Prime Capital investment in Series C - VYNE Therapeutics

venbio_image

venBio Partners

venBio Partners investment in Series C - VYNE Therapeutics

aisling-capital_image

Aisling Capital

Aisling Capital investment in Series C - VYNE Therapeutics

novo-a-s_image

Novo Holdings

Novo Holdings investment in Series C - VYNE Therapeutics

vivo-capital_image

Vivo Capital

Vivo Capital investment in Series C - VYNE Therapeutics

bay-city-capital_image

Bay City Capital

Bay City Capital investment in Series C - VYNE Therapeutics

presidio-partners_image

Presidio Partners

Presidio Partners investment in Series B - VYNE Therapeutics

Official Site Inspections

http://www.vynetherapeutics.com Semrush global rank: 10.18 M Semrush visits lastest month: 31

  • Host name: 141.193.213.10
  • IP address: 141.193.213.10
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "VYNE Therapeutics" on Search Engine